BloodScan Biotech Inc. is a biotechnology company dedicated to precision oncology. Founded through technology transfer from a research team at the University of Michigan, BloodScan focuses on advancing innovations in liquid biopsy with the goal of becoming a key global driver in early cancer detection and disease monitoring. Our flagship product, Labyrinth One, is the world’s only liquid biopsy system capable of achieving tissue-biopsy-comparable performance. The system enables stable, fully automated enrichment of circulating tumor cells (CTCs) and delivers ultra-sensitive capabilities for early cancer screening and monitoring. Three Core Advantages: 1. Reliable CTC Isolation and Monitoring in Advanced Cancer – Enables disease monitoring and treatment response assessment in late-stage patients. 2. Tissue-Biopsy-Comparable Performance – Provides accuracy and biological integrity comparable to conventional histopathology. 3. Ultra-Sensitive Early Cancer Screening – Enhances early cancer detection rates to support more precise and timely treatment decisions. Our vision is to establish CTCs as a central pillar of next-generation cancer diagnostics, empowering healthcare systems worldwide to deliver earlier, more precise, and more personalized cancer care. | BloodScan Biotech Inc. Pioneering Liquid Biopsy for Precision Oncology BloodScan Biotech Inc. is a biotechnology company at the forefront of next-generation liquid biopsy technologies, committed to transforming cancer diagnostics through precision medicine. Established in 2023 as a spin-off from the University of Michigan, BloodScan focuses on advancing circulating tumor cell (CTC) isolation to improve early cancer detection, real-time treatment monitoring, and personalized therapeutic decision-making. The heart of BloodScan’s innovation is the Labyrinth One – Automated CTC Enrichment System, a compact, benchtop platform designed for high-throughput, label-free isolation of viable CTCs directly from blood samples. Unlike traditional antibody-based capture technologies, Labyrinth One utilizes microfluidic separation to deliver exceptional purity, recovery, and reproducibility—all within a 15-minute workflow. This allows for seamless integration into both clinical and research laboratory settings, enabling routine use of CTCs for diagnostics and translational oncology research. BloodScan’s mission is to bridge the gap between academic innovation and clinical implementation. Through strategic partnerships with research institutes, oncology centers, and clinical laboratories, the company aims to accelerate the adoption of liquid biopsy technologies and expand access to non-invasive cancer diagnostics that can meaningfully improve patient outcomes.
Bioptimus
Bioptimus provides the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine. We offer foundational models that—just like biology—are greater than the sum of their parts. Models that understand tissue morphology and gene expression, but more importantly, models that understand and predict how each of these scales will influence the other.
BioOptions
BIOIOPTIONS is your go-to for high-quality fresh human tumor and blood specimens partner. Our extensive bank of frozen samples, FFPE blocks, and TMA’s provides researchers with a vast selection of disease states from across the country – all collected in line with federal regulations. Get started on your studies today with overnight deliveries.
Biognosys
Biognosys is a leading contract research organization (CRO) specializing in proteomics services for early-stage R&D through clinical trial biomarker monitoring. Partnering with the most innovative biotech and pharmaceutical companies worldwide, Biognosys utilizes unique, patented technologies and high-resolution mass spectrometry to quantify thousands of proteins with unmatched precision, depth, and throughput. With laboratories near Zurich, Switzerland and Boston, Massachusetts, Biognosys combines scientific expertise and next-generation proteomics to accelerate drug discovery and development, and supports translational and preclinical research, and clinical trials for precision medicine. Learn more at www.biognosys.com
BioDot
BioDot has provided low-volume dispensing solutions to the Diagnostics, Drug Discovery, and Life Sciences fields since 1994. Our systems deliver accurate microliter-to-picoliter dispensing, enabling laboratories to integrate automation and miniaturization into workflows while maintaining sample integrity and experimental reproducibility. Visit our booth to see our new dynamic platform in operation and explore its applications in modern laboratory workflows.
BioDuro
BioDuro, an Advent International portfolio company is a trusted, leading contract research development, and manufacturing organization (CRDMO) for 30 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US with operations in China, totaling 2,000+ scientists and 7 global sites across 6 cities. Core expertise includes small and large molecule discovery, development and scale-up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people-focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate our development timeline. For more information about BioDuro, please visit our website at www.bioduro-sundia.com | BioDuro, an Advent portfolio company, is a CRDMO with a 30-year proven track record. Headquartered in Irvine, California, BioDuro employs more than 2,000 scientists with deep expertise in small- and large-molecule discovery, development, and manufacturing. We provide fully integrated drug discovery services spanning chemistry, biology, and pharmacokinetics (DMPK), along with comprehensive IND-enabling capabilities, including both drug substance and drug product development.
Biocare Medical
Biocare Medical, LLC is an innovator in developing and supplying world class automated immunohistochemistry instrumentation, and the full range of reagents for IHC lab testing. Biocare is the market leader in simultaneous Multiplex IHC tests which provide increased confidence at critical diagnostic decision points, impacting patient therapy while accelerating turnaround time. Biocare’s advanced micro-polymer™ detection enables unsurpassed specificity and sensitivity.
Bio X Cell
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Bio X Cell antibodies deliver reliable, reproducible results across in vivo and in vitro organoid and organ-on-chip studies allowing researchers to confidently scale their experiments from milligrams to grams and progress from discovery through translational workflows without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.
Bio-Techne
Bio-Techne is a global developer, manufacturer and supplier of high-quality reagents, analytical instruments, and precision diagnostics. Whether you’re at the cutting edge of academic research, translating basic discoveries to therapeutic leads, or at a facility that requires the highest level of diagnostic testing, our award-winning tools and solutions empower scientists and clinicians to achieve reproducible and consistent results. Trusting Bio-Techne means choosing confidence that every solution you use will help move you toward better answers. | Bio-Techne offers precision medicine services to pharma partners spanning the continuum from biomarker discovery to post-market commercialization of companion diagnostic products. Our platform-agnostic approach to biomarker discovery and clinical trial assay development, paired with clinical trial sample testing readiness at our CLIA labs and international regulatory expertise allows us to offer customizable solutions so that a pharma partner can improve their drug’s likelihood of success and deliver novel treatments to the patients most likely to benefit, faster.